NEW YORK (TheStreet) -- British Prime Minister Cameron has reportedly been urged AstraZeneca (AZN) chairman Johansson not to give ammunition to Pfizer's (PFE) $106 billion bid as the company prepares to increase its defense against the move by focusing on a range of new drugs under development, according to the Financial Times.
Shares of AstraZeneca are down -1.28% to $79.98.
Johansson cautioned the prime minister that the government's active engagement with Pfizer could allow the group to claim that he supports the deal, sources told the Times.
TheStreet Ratings team rates ASTRAZENECA PLC as a Buy with a ratings score of B-. TheStreet Ratings Team has this to say about their recommendation:
"We rate ASTRAZENECA PLC (AZN) a BUY. This is driven by a few notable strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income."
Highlights from the analysis by TheStreet Ratings Team goes as follows:
- The current debt-to-equity ratio, 0.45, is low and is below the industry average, implying that there has been successful management of debt levels. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.05, which illustrates the ability to avoid short-term cash problems.
- Compared to its closing price of one year ago, AZN's share price has jumped by 57.18%, exceeding the performance of the broader market during that same time frame. Looking ahead, the stock's sharp rise over the last year has already helped drive it to a level which is relatively expensive compared to the rest of its industry. We feel, however, that other strengths this company displays justify these higher price levels.
- ASTRAZENECA PLC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has suffered a declining pattern of earnings per share over the past two years. However, we anticipate this trend to reverse over the coming year. During the past fiscal year, ASTRAZENECA PLC reported lower earnings of $2.04 versus $4.94 in the prior year. This year, the market expects an improvement in earnings ($4.25 versus $2.04).
- AZN, with its decline in revenue, slightly underperformed the industry average of 2.3%. Since the same quarter one year prior, revenues slightly dropped by 2.8%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.
- Net operating cash flow has decreased to $2,478.00 million or 12.99% when compared to the same quarter last year. Despite a decrease in cash flow ASTRAZENECA PLC is still fairing well by exceeding its industry average cash flow growth rate of -40.05%.
- You can view the full analysis from the report here: AZN Ratings Report